Soleno Therapeutics(US:SLNO) Prnewswire·2025-11-08 00:30Company Overview - Soleno Therapeutics, Inc. (NASDAQ: SLNO) is under investigation for potential violations of U.S. federal securities laws, focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1][2]. Recent Developments - On March 26, 2025, Soleno announced FDA approval for VYKAT XR (diazoxide choline) extended-release tablets, intended for treating hyperphagia in individuals with Prader-Willi syndrome aged 4 and older [3]. - During a quarterly earnings call on November 4, 2025, Soleno disclosed a discontinuation rate of approximately 8% for VYKAT XR due to adverse effects by the end of Q3 2025. The CEO acknowledged a disruption in the product's launch trajectory following a short seller report released in mid-August, which led to a decrease in start forms and an increase in discontinuations for non-serious adverse events [4]. Market Reaction - Following the earnings call and the revelation of the discontinuation rate, Soleno's share price experienced a decline of over 26% [4].